Tag

Tumor Heterogeneity

All articles tagged with #tumor heterogeneity

Spatial-ATAC-Hi-C maps tissue-wide 3D genome and chromatin accessibility
science2 days ago

Spatial-ATAC-Hi-C maps tissue-wide 3D genome and chromatin accessibility

A new microfluidic Spatial-ATAC-Hi-C platform enables simultaneous, genome-wide mapping of 3D genome architecture and chromatin accessibility directly in tissue sections, preserving spatial context. Applied to mouse and human brains and glioma samples, it reveals cell-type–specific 3D genome features and chromatin loops, detects spatial copy-number variations and structural variants, and uncovers clonal heterogeneity across tumor regions, offering a powerful tool for studying spatial gene regulation in health and disease.

Developmental cell states drive heterogeneity in supratentorial ependymomas
science5 months ago

Developmental cell states drive heterogeneity in supratentorial ependymomas

A multidimensional study integrating single-cell and spatial transcriptomics with live-cell imaging reveals two progenitor-like states—neuroepithelial-like and embryonic-like—and diverse spatial architectures in supratentorial ependymomas. Brain-resident cells can shift tumor cells toward neuronal-like, migratory phenotypes, highlighting developmental origins of heterogeneity and suggesting potential therapeutic angles.

The Impact of Tumor Heterogeneity on Immunogenicity in Mismatch Repair Deficient Tumors
cancer-immunotherapy2 years ago

The Impact of Tumor Heterogeneity on Immunogenicity in Mismatch Repair Deficient Tumors

Tumor heterogeneity can impair immunogenicity in mismatch repair deficient (MMRd) tumors, potentially leading to immunotherapy failure. While high tumor mutational burden (TMB) is associated with exceptional immunotherapy responses, some MMRd patients do not experience clinical benefit. Recent research suggests that high intra-tumoral heterogeneity can offset immunogenicity in sporadic MMRd tumors, highlighting the need for further investigation into the mechanisms underlying immunotherapy resistance.